Suneet Agarwal

List of Publications by Year in descending order

38 papers	1,386 citations	430874 18 h-index	414414 32 g-index
39 all docs	39 docs citations	39 times ranked	2297 citing authors

#	Article	IF	Citations
1	Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. Journal of Pediatrics, 2021, 230, 55-61.e4.	1.8	14
2	The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood, 2021, 138, 898-911.	1.4	27
3	Mitochondrial function in development and disease. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	48
4	Telomerase RNA recruits RNA polymerase II to target gene promoters to enhance myelopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2015528118.	7.1	8
5	Hepatic vascular remodelling in a patient with dyskeratosis congenita. Histopathology, 2021, , .	2.9	0
6	Congenital Xâ€linked Neutropenia with Myelodysplasia and Somatic Tetraploidy due to a Germline Mutation in SEPT6. American Journal of Hematology, 2021, , .	4.1	1
7	Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival. ERJ Open Research, 2020, 6, 00003-2020.	2.6	33
8	Telomerase RNA processing: Implications for human health and disease. Stem Cells, 2020, 38, 1532-1543.	3.2	28
9	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood, 2020, 136, 3070-3081.	1.4	25
10	Small-Molecule PAPD5 Inhibitors Restore Telomerase Activity in Patient Stem Cells. Cell Stem Cell, 2020, 26, 896-909.e8.	11.1	57
11	Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis, 2019, 22, 95-102.	7.2	45
12	Evaluation and Management of Hematopoietic Failure in Dyskeratosis Congenita. Hematology/Oncology Clinics of North America, 2018, 32, 669-685.	2.2	41
13	Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. Blood, 2018, 132, 796-796.	1.4	3
14	Congenital X-Linked Myelodysplasia with Tetraploidy Is Associated with De Novo Germline C-Terminal Mutation of SEPT6, a Septin Filament Protein. Blood, 2018, 132, 644-644.	1.4	0
15	Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies. Ophthalmic Genetics, 2017, 38, 51-60.	1.2	17
16	Pulmonary arteriovenous malformations: an uncharacterised phenotype of dyskeratosis congenita and related telomere biology disorders. European Respiratory Journal, 2017, 49, 1601640.	6.7	41
17	Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Science Translational Medicine, 2017, 9, .	12.4	87
18	Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPRâ€“Cas9 genome editing. Nature Biomedical Engineering, 2017, 1, 878-888.	22.5	83

#	Article	IF	Citations
19	Exudative Vitreoretinopathy in Dyskeratosis Congenita. Ophthalmology, 2017, 124, 1246.	5.2	5
20	Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation. PLoS ONE, 2016, 11, e0162409.	2.5	30
21	A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. Blood, 2016, 128, 2089-2092.	1.4	7
22	Posttranscriptional manipulation of TERC reverses molecular hallmarks of telomere disease. Journal of Clinical Investigation, 2016, 126, 3377-3382.	8.2	45
23	Poly(A)-specific ribonuclease (PARN) mediates 3â€²-end maturation of the telomerase RNA component. Nature Genetics, 2015, 47, 1482-1488.	21.4	149
24	Mutations in the Poly(A)-Specific Ribonuclease (PARN) Impair Telomerase RNA 3' End Maturation in Dyskeratosis Congenita Patients. Blood, 2015, 126, 669-669.	1.4	1
25	Simultaneous sequencing of oxidized methylcytosines produced by TET/JBP dioxygenases in Coprinopsis cinerea. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5149-58.	7.1	25
26	Full Donor Myeloid Engraftment with Minimal Toxicity in Dyskeratosis Congenita Patients Undergoing Allogeneic Bone Marrow Transplantation without Radiation or Alkylating Agents. Blood, 2014, 124, 2941-2941.	1.4	4
27	Induced Pluripotent Stem Cells with a Mitochondrial DNA Deletion. Stem Cells, 2013, 31, 1287-1297.	3.2	92
28	A Young Adult with Aplastic Anemia and Gray Hair. Clinical Chemistry, 2013, 59, 47-50.	3.2	0
29	GATA2 Mutations In Pediatric Myelodysplastic Syndromes and Bone Marrow Failure. Blood, 2013, 122, 1520-1520.	1.4	3
30	Pearson Marrow Pancreas Syndrome In a Cohort Of Diamond Blackfan Anemia Patients. Blood, 2013, 122, 1226-1226.	1.4	0
31	CTC1 Mutations in a patient with dyskeratosis congenita. Pediatric Blood and Cancer, 2012, 59, 311-314.	1.5	115
32	Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Cell Research, 2011, 21, 1157-1160.	12.0	19
33	AID for reprogramming. Cell Research, 2010, 20, 253-255.	12.0	6
34	Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature, 2010, 464, 292-296.	27.8	302
35	Translational potential of patientâ€specific human pluripotent stem cells. FASEB Journal, 2010, 24, 64.1.	0.5	0
36	Derivation of Disease-Free Induced Pluripotent Stem Cells From Patients with Pearson Marrow Pancreas Syndrome. Blood, 2010, 116, 3-3.	1.4	0

#	Article	IF	Citations
37	Impaired Hydroxylation of 5-Methylcytosine In TET2 mutated Patients with Myeloid Malignancies. Blood, 2010, 116, 1-1.	1.4	24
38	Telomere Elongation in Dyskeratosis Congenita Induced Pluripotent Stem Cells.. Blood, 2009, 114, 497-497.	1.4	1